Placlitaxel drug-coated balloons reduce MACE and revascularization versus limus-eluting stents in bifurcation lesions
Drug-coated balloons cut heart risks for side branch lesions better than stents
This meta-analysis reviews data from patients with side branch lesions in true coronary bifurcations undergoing percutaneous coronary interv…
A review of 898 patients shows drug-coated balloons significantly reduce heart risks compared to stents for specific coronary artery blockag…
Docetaxel chemotherapy is highly suspect for causing acute myocardial infarction in a low-risk triple-negative breast cancer patient
Docetaxel chemotherapy linked to rare heart attack in breast cancer patient
This case report and literature review examines acute myocardial infarction following docetaxel chemotherapy in a patient with triple-negati…
A rare heart attack occurred after docetaxel chemotherapy in a patient with triple-negative breast cancer. This case review suggests the dru…
Systematic review and meta-analysis of drug-coated balloons versus drug-eluting stents in coronary artery disease
Meta-analysis links drug balloons to higher heart risks
This systematic review and meta-analysis evaluated drug-coated balloons (DCB) versus drug-eluting stents (DES) in 8,123 patients with corona…
A review of 8,123 patients found drug-coated balloons for heart arteries may raise risks of repeat procedures and cardiac death compared to …
Case report of penpulimab, nab-paclitaxel, and anlotinib in porocarcinoma
Immunotherapy-Chemo Mix Shows Promise Against Stubborn Skin Cancer
This case report and literature review describes a 78-year-old female with porocarcinoma treated with penpulimab plus nab-paclitaxel, then a…
• A rare skin cancer slowed with immunotherapy plus chemo • Helps patients with porocarcinoma lacking treatment options • Still experimental
Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
Five-year follow-up shows pembrolizumab extends life for Chinese lung cancer patients with high PD-L1
This Phase 3 trial evaluated pembrolizumab monotherapy against chemotherapy in Chinese patients with previously untreated locally advanced o…
A five-year look at a Chinese lung cancer trial shows pembrolizumab improved survival compared to chemotherapy for patients with high PD-L1 …
Capivasertib-paclitaxel fails to improve overall survival in metastatic TNBC
New drug combo did not extend life for metastatic triple-negative breast cancer patients in this trial
This phase III RCT in 812 patients with previously untreated metastatic triple-negative breast cancer found that adding capivasertib to pacl…
A large global trial found that adding capivasertib to paclitaxel did not improve overall survival for patients with metastatic triple-negat…
Paclitaxel-coated balloons and sirolimus-eluting stents in noncomplex coronary bifurcation lesions
Drug coated balloons show similar results for certain artery blockages
This randomized noninferiority trial subgroup analysis evaluated 2,257 participants with de novo coronary lesions.
New data suggests drug coated balloons may work as well as traditional stents for specific types of coronary artery blockages.
Camrelizumab plus nab-paclitaxel showed modest activity in previously treated advanced urothelial carcinoma patients
New Treatment Extends Life for Bladder Cancer Patients
This multicenter Phase II study evaluated camrelizumab plus nab-paclitaxel in 60 patients with advanced urothelial carcinoma who progressed …
For years, Mark, 64, thought he’d beaten cancer.
Histology-derived gene-expression signatures predict distant recurrence-free interval and chemotherapy benefit in early breast cancer cohorts
New Tool Predicts Breast Cancer Recurrence From Old Slides
This multi-cohort study evaluated histology-derived gene-expression signatures from routine hematoxylin and eosin slides compared with clini…
A simple AI analysis of old biopsy slides can now predict which breast cancer patients face higher risk of recurrence and who truly benefits…
Phase III trial indicates ultra-low-dose nivolumab may improve survival over chemotherapy in advanced solid tumors
A Tiny Dose of This Cancer Drug Is Outperforming Chemo
This Phase III randomized trial evaluated ultra-low-dose nivolumab against standard chemotherapy in patients with advanced solid tumors prog…
Giving a much smaller dose of a powerful cancer drug can extend life with fewer side effects, making treatment more tolerable and accessible…
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
New Drug Combo Extends Survival for Tough Ovarian Cancer
This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participant…
This new combination offers a meaningful survival boost for women with recurrent ovarian cancer that has become resistant to standard treatm…
Neoadjuvant Chemoimmunotherapy Alters Tumor Microenvironment in Esophageal Cancer
Combination therapy may help overcome resistance in esophageal cancer
This Phase 3 RCT in 55 patients with locally advanced esophageal squamous cell carcinoma compared neoadjuvant chemotherapy alone versus comb…
A small trial suggests combination therapy might help overcome resistance in esophageal cancer by targeting specific immune cells.